Skip to main content
Retour
SOLV logo

Solventum Corporation

Qualité des données : 100%
Survendu
SOLV
NYSE Healthcare Medical - Care Facilities
64,03 €
▼ 1,66 € (-2,53%)
Cap. Boursière : 11,11B
Fourchette du Jour
62,80 € 64,87 €
Fourchette 52 Semaines
60,70 € 88,20 €
Volume
1 344 547
Moyenne 50J / 200J
75,06 € / 75,07 €
Clôture Précédente
65,69 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 7,1 0,4
P/B 2,2 2,9
ROE % 38,9 3,7
Net Margin % 18,7 3,9
Rev Growth 5Y % 0,5 10,0
D/E 1,0 0,2

Objectif de Cours des Analystes

Hold
95,80 € +49.6%
Low: 77,00 € High: 105,00 €
P/E Prévisionnel
10,2
BPA Prévisionnel
6,48 €
Croissance BPA (est.)
+0,0%
CA Est.
8,2 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2029 0,00 €
0,00 € – 0,00 €
9 B 0
FY2028 7,83 €
3,96 € – 11,70 €
8,8 B 2
FY2027 7,07 €
6,92 € – 7,24 €
8,5 B 7

Points Clés

Revenue grew 0,47% annually over 5 years — modest growth
Earnings grew 224,84% over the past year
ROE of 38,86% indicates high profitability
Net margin of 18,69% shows strong profitability
Negative free cash flow of -10,00M
P/E of 7,14 — trading at a low valuation

Croissance

Revenue Growth (5Y)
0,47%
Revenue (1Y)0,86%
Earnings (1Y)224,84%
FCF Growth (3Y)N/A

Qualité

Return on Equity
38,86%
ROIC16,22%
Net Margin18,69%
Op. Margin26,20%

Sécurité

Debt / Equity
1,00
Current Ratio1,23
Interest Coverage6,29

Valorisation

P/E Ratio
7,14
P/B Ratio2,20
EV/EBITDA7,00
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0,86% Revenue Growth (3Y) 0,78%
Earnings Growth (1Y) 224,84% Earnings Growth (3Y) 7,52%
Revenue Growth (5Y) 0,47% Earnings Growth (5Y) 1,60%
Profitability
Revenue (TTM) 8,33B Net Income (TTM) 1,56B
ROE 38,86% ROA 10,89%
Gross Margin 53,47% Operating Margin 26,20%
Net Margin 18,69% Free Cash Flow (TTM) -10,00M
ROIC 16,22% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,00 Current Ratio 1,23
Interest Coverage 6,29 Dividend Yield 0,00%
Valuation
P/E Ratio 7,14 P/B Ratio 2,20
P/S Ratio 1,33 PEG Ratio 0,04
EV/EBITDA 7,00 Dividend Yield 0,00%
Market Cap 11,11B Enterprise Value 15,27B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 8,33B 8,25B 8,20B 8,13B 8,17B
Net Income 1,56B 479,00M 1,35B 1,34B 1,46B
EPS (Diluted) 8,88 2,76 7,79 7,79 8,47
Gross Profit 4,45B 4,59B 4,69B 4,70B 4,92B
Operating Income 2,18B 1,04B 1,69B 1,69B 1,88B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 14,29B 14,46B 13,94B 13,59B 14,08B
Total Liabilities 9,25B 11,50B 2,28B 1,85B 2,02B
Shareholders' Equity 5,05B 2,96B 11,67B 11,74B 12,06B
Total Debt 5,04B 8,01B 8,30B 0,0 0,0
Cash & Equivalents 878,00M 762,00M 194,00M 61,00M 91,00M
Current Assets 3,86B 3,25B 2,52B 2,23B 2,19B
Current Liabilities 3,14B 2,70B 1,73B 1,31B 1,41B

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches

Activité Récente

Entré Contrarian Investing (David Dreman)
Mar 24, 2026